Premexa Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 5 Year, 4 Days
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 122.16%
- Profit Growth 444.59%
- Ebitda 292.04%
- Net Worth 151.65%
- Total Assets 70.39%
About Premexa Lifesciences
Premexa Lifesciences Private Limited (PLPL) is a Private Limited Indian Non-Government Company incorporated in India on 19 February 2020 (Five years 4 days old ). Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Karunakar Chinta, Kannegulla Sridhar, and Veeresham Murki serve as directors at the Company.
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24304TG2020PTC139376
- Company No.
139376
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Feb 2020
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Premexa Lifesciences?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Karunakar Chinta  | Director | 19-Feb-2020 | Current |
| Kannegulla Sridhar | Director | 19-Feb-2020 | Current |
| Veeresham Murki | Director | 19-Feb-2020 | Current |
Financial Performance of Premexa Lifesciences.
Premexa Lifesciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 122.16% increase. The company also saw a substantial improvement in profitability, with a 444.59% increase in profit. The company's net worth Soared by an impressive increase of 151.65%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Premexa Lifesciences?
In 2023, Premexa Lifesciences had a public holding of 20.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Double Tree By Kvp Hospitality LlpVeeresham Murki is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Premexa Lifesciences?
Unlock and access historical data on people associated with Premexa Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Premexa Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Premexa Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.